Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SeaStar Medical Holding (ICUCW) Research & Development (2023 - 2025)

SeaStar Medical Holding's Research & Development history spans 3 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Research & Development fell 19.65% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $7.5 million, down 17.43%, while the annual FY2025 figure was $7.5 million, 17.43% down from the prior year.
  • Research & Development reached $2.2 million in Q4 2025 per ICUCW's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.7 million in Q4 2024 to a low of $1.0 million in Q2 2025.
  • Average Research & Development over 3 years is $1.9 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 133.02% in 2024, then plummeted 55.57% in 2025.
  • A 3-year view of Research & Development shows it stood at $1.2 million in 2023, then soared by 133.02% to $2.7 million in 2024, then fell by 19.65% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ICUCW's Research & Development are $2.2 million (Q4 2025), $1.8 million (Q3 2025), and $1.0 million (Q2 2025).